Vistin Pharma Management
Management criteria checks 4/4
Vistin Pharma's CEO is Magnus Tolleshaug, appointed in Feb 2022, has a tenure of 2.92 years. total yearly compensation is NOK2.24M, comprised of 81% salary and 19% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth NOK1.76M. The average tenure of the management team and the board of directors is 2.9 years and 6.7 years respectively.
Key information
Magnus Tolleshaug
Chief executive officer
NOK 2.2m
Total compensation
| CEO salary percentage | 81.0% |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.9yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors
Sep 18
Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?
Feb 23A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)
Sep 09Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)
Aug 25Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First
Mar 15We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate
Feb 20
Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?
Jan 29The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It
Jan 08Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?
Dec 16Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?
Nov 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | NOK 61m |
| Jun 30 2024 | n/a | n/a | NOK 68m |
| Mar 31 2024 | n/a | n/a | NOK 56m |
| Dec 31 2023 | NOK 2m | NOK 2m | NOK 46m |
| Sep 30 2023 | n/a | n/a | NOK 45m |
| Jun 30 2023 | n/a | n/a | NOK 14m |
| Mar 31 2023 | n/a | n/a | NOK 7m |
| Dec 31 2022 | NOK 3m | NOK 2m | -NOK 5m |
| Sep 30 2022 | n/a | n/a | -NOK 15m |
| Jun 30 2022 | n/a | n/a | -NOK 7m |
| Mar 31 2022 | n/a | n/a | NOK 929k |
| Dec 31 2021 | NOK 2m | NOK 1m | NOK 25m |
| Sep 30 2021 | n/a | n/a | NOK 26m |
| Jun 30 2021 | n/a | n/a | NOK 30m |
| Mar 31 2021 | n/a | n/a | NOK 43m |
| Dec 31 2020 | NOK 2m | NOK 1m | -NOK 97m |
Compensation vs Market: Magnus's total compensation ($USD197.06K) is below average for companies of similar size in the Norwegian market ($USD282.92K).
Compensation vs Earnings: Magnus's compensation has been consistent with company performance over the past year.
CEO
Magnus Tolleshaug
2.9yrs
Tenure
NOK 2,238,000
Compensation
Mr. Magnus Tolleshaug Serves as a Commercial Director at Vistin Pharma ASA and served as its Interim Chief Executive Officer since February 16, 2022 until January 1, 2024 and serves as its Chief Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Commercial Officer & Commercial Director | 2.9yrs | NOK 2.24m | 0.17% NOK 1.8m | |
| Chief Financial Officer | 4.8yrs | NOK 2.34m | no data | |
| Chief Operating Officer | less than a year | NOK 2.18m | 0.17% NOK 1.8m | |
| Director of Technical Service & Sales | no data | no data | no data |
2.9yrs
Average Tenure
Experienced Management: VISTN's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Chairman of the Board | 4.6yrs | NOK 441.00k | no data | |
| Independent Director | 10yrs | NOK 210.00k | 3.51% NOK 36.5m | |
| Independent Director | 6.7yrs | NOK 231.00k | no data | |
| Independent Director | 4.6yrs | NOK 210.00k | no data | |
| Employee Representative Director | 10yrs | NOK 210.00k | 0.0050% NOK 51.5k | |
| Independent Director | 4.7yrs | NOK 210.00k | no data | |
| Employee Representative Director | 7.3yrs | NOK 210.00k | no data |
6.7yrs
Average Tenure
61yo
Average Age
Experienced Board: VISTN's board of directors are considered experienced (6.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 01:50 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vistin Pharma ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |